Reference is made to the stock exchange announcements made by Inify Laboratories AB (the "Company") on 16 December 2024 regarding the allocation of 30,202,366 new shares in a private placement (the "Private Placement"), and on 23 January 2025 regarding the allocation of 3,464,300 new shares in a subsequent offering (the "Subsequent Offering").

The Board of Directors of the Company has today, 12 February 2025, resolved to issue the 30,202,366 new shares in the Private Placement (the "Private Placement Shares") and the 3,464,300 new shares in the Subsequent Offering (the "Subsequent Offer Shares"). Subject to timely registration of the share capital increase pertaining to the Private Placement and the Subsequent Offering with the Swedish Companies Registration Office (Sw. Bolagsverket), the Private Placement Shares and the Subsequent Offer Shares are expected to be delivered on or about 17 February 2025.

The 714,676 Private Placement Shares and the 339,063 Subsequent Offer Shares that were initially allocated to Auris AS under its guarantee undertaking have been re-allocated to Tauri AS subject to an agreement between Auris AS, Tauri AS, the Company and the Manager. Auris AS and Tauri AS are companies ultimately owned by the same person, and the re-allocation has been made upon request from the owner.

As Monsun AS and Gallivant S.à r.l. have received a positive decision from the Inspectorate of Strategic Products pursuant to the Screening of Foreign Direct Investment Act, the allocation of shares to Monsun AS and Gallivant S.à r.l. is no longer conditional.

Advisors

SpareBank 1 Markets AS has been appointed as financial advisor in connection with the Private Placement and the Subsequent Offering. Schjødt law firm acts as legal counsel to the Company.

For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com

This information is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI -supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision (https://www.contextvision.com/), with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.